Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

New immunotherapy compound effective, safe in ALL patients with minimal...

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

New immunotherapy compound effective, safe in ALL patients with minimal residual disease ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )

T cell therapy leading to prolonged remission for children with aggressive...

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA

T cell therapy leading to prolonged remission for children with aggressive leukaemia ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

ASH 2014: Expert discussion on the latest in AML

Prof Alan Burnett and Prof Sergio Amadori

ASH 2014: Expert discussion on the latest in AML ( Prof Alan Burnett and Prof Sergio Amadori )

Pembrolizumab may bring hope for patients with Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Pembrolizumab may bring hope for patients with Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Immunology highlights from ASH 2014

Dr Catherine Bollard - George Washington University, Washington, USA

Immunology highlights from ASH 2014 ( Dr Catherine Bollard - George Washington University, Washington, USA )

Comment: T cell therapy for children with aggressive leukaemia

Dr Catherine Bollard - George Washington University, Washington, USA

Comment: T cell therapy for children with aggressive leukaemia ( Dr Catherine Bollard - George Washington University, Washington, USA )

Comment: Blinatumomab for acute lymphocytic leukaemia

Dr Catherine Bollard - George Washington University, Washington, USA

Comment: Blinatumomab for acute lymphocytic leukaemia ( Dr Catherine Bollard - George Washington University, Washington, USA )

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma

Dr Catherine Bollard - George Washington University, Washington, USA

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma ( Dr Catherine Bollard - George Washington University, Washington, USA )

ASH 2014: Expert discussion on the latest in CLL

Prof John Gribben and Prof Stephan Stilgenbauer

ASH 2014: Expert discussion on the latest in CLL ( Prof John Gribben and Prof Stephan Stilgenbauer )

Engineering stem cell resistance to HIV for two-pronged approach to HIV...

Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA

Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma ( Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA )

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive...

Dr Thomas Martin, MD, University of California, San Francisco, USA

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma ( Dr Thomas Martin, MD, University of California, San Francisco, USA )

More from ecancer